Nasdaq's 15min chart shows KDJ Death Cross, Bearish Marubozu signal.

The Nasdaq's 15-minute chart has recently exhibited a KDJ Death Cross and a Bearish Marubozu pattern at 10:20 on October 20, 2025, at 11:15. This indicates a shift in the stock price's momentum towards the downside, potentially leading to further decreases. The sellers currently dominate the market, and this bearish momentum is likely to persist.

Adaptimmune Therapeutics Plc (ADAP), a clinical-stage biopharmaceutical company focused on developing T-cell receptor therapies for solid tumor cancers, has seen a significant shift in its stock price momentum following recent technical indicators. On October 20, 2025, at 10:20 and 11:15, the Nasdaq's 15-minute chart exhibited a KDJ Death Cross and a Bearish Marubozu pattern, respectively. These patterns indicate a potential reversal in the stock's price trend, signaling a shift towards the downside.

The KDJ Death Cross occurs when the K-line crosses below the D-line on the KDJ indicator, suggesting a bearish trend. The Bearish Marubozu pattern, characterized by a candle with no wicks, signifies a strong selling pressure. These technical indicators suggest that the selling pressure is dominant, and the stock may continue to decline.

Investors should closely monitor Adaptimmune's stock performance and consider the implications of these technical signals. The company recently announced its intention to delist from the Nasdaq, which may further impact its stock price, according to StockTitan. The delisting decision aims to reduce costs associated with SEC reporting, Sarbanes-Oxley compliance, and Nasdaq listing requirements.

Adaptimmune's financial results for Q2 2025 also highlight the company's ongoing challenges. The company reported a net loss of $30.3 million and a cash position of $26.1 million, with revenue of $13.7 million. The company's Q2 Tecelra sales achieved $11.1 million, representing over 150% growth compared to Q1 2025 . However, the company's substantial debt and the need for further restructuring may contribute to the bearish sentiment.

Investors should remain cautious and monitor Adaptimmune's financial health and regulatory filings. The company's ability to continue as a going concern remains uncertain, and the recent technical indicators suggest that the stock may face further downward pressure.